COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Alitretinoin in the Treatment of Chronic Hand Eczema

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00519675
Recruitment Status : Completed
First Posted : August 23, 2007
Last Update Posted : July 19, 2010
Information provided by:
Basilea Pharmaceutica

Brief Summary:
The purpose of the study is to investigate the safety and efficacy of alitretinoin in chronic hand eczema that is refractory to topical corticosteroids.

Condition or disease Intervention/treatment Phase
Eczema Drug: alitretinoin Phase 3

Detailed Description:
Chronic hand eczema is a frequent and distressing disease. The course of the disease is of chronic-relapsing nature. In a phase III study alitretinoin was clinically effective for patients with severe chronic hand eczema refractory to topical treatment. This study investigates the safety and efficacy of alitretinoin who previously have participated in a clinical trial involving alitretinoin.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open Label Treatment of Patients With Chronic Hand Dermatitis Who Have Participated in a Previous Clinical Trial Involving Oral Alitretinoin
Study Start Date : May 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eczema

Primary Outcome Measures :
  1. Safety assessments

Secondary Outcome Measures :
  1. Efficacy (Physicians Global Assessment)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Previous participation in therapeutic trials involving chronic hand eczema
  • Relapse of chronic hand eczema, defined as 75% of the baseline initial total lesion symptom score

Exclusion Criteria:

  • Patients whose disease is adequately controlled by standard non-medicated skin care and topical corticosteroid therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00519675

Layout table for location information
Paris, France
Saint Etienne, France
Berlin, Germany
Dresden, Germany
Sponsors and Collaborators
Basilea Pharmaceutica
Layout table for investigator information
Study Director: Jürgen Maares, MD Basilea Pharmaceutica
Layout table for additonal information Identifier: NCT00519675    
Other Study ID Numbers: BAP00731
First Posted: August 23, 2007    Key Record Dates
Last Update Posted: July 19, 2010
Last Verified: July 2010
Keywords provided by Basilea Pharmaceutica:
Chronic hand eczema
Chronic hand dermatitis
Patients with chronic hand eczema, who are refractory to topical corticosteroids
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases
Skin Diseases, Eczematous
Antineoplastic Agents
Dermatologic Agents